US2022135662A1PendingUtilityA1

Novel use of regulatory t cell-specific surface protein lrig-1

Assignee: GOOD T CELLS INCPriority: Jan 24, 2011Filed: Jan 13, 2022Published: May 5, 2022

Est. expiryJan 24, 2031(~4.5 yrs left)· nominal 20-yr term from priority

C12N 15/1138A61K 35/17C12Q 1/68A61P 35/00C07K 14/47C12N 2310/11G01N 33/9493G01N 33/15C12N 2310/14C12N 15/113C12Q 2600/158A61K 38/00C12Q 1/6876G01N 33/505C12Q 2600/178C07K 16/18C12N 2310/17G01N 33/6854G01N 33/6872G01N 33/5302C12Q 2600/136G01N 33/5023

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention relates to a novel use of regulatory T cell-specific surface protein Lrig-1, and more specifically to an immunosuppressive agent comprising siRNA which inhibits the expression of surface protein Lrig-1. In addition, the invention relates to a method for screening an immunosuppressive agent which inhibits proteins of Lrig-1 or genes encoding the proteins. As a result, an immunosuppressive agent with low side effects and high specificity can be developed.

Claims

exact text as granted — not AI-modified

1 . A method for treating immune-related diseases comprising administering an effective amount of a regulatory T cell to a subject with immune-related diseases, wherein the regulatory T cell has Lrig-1 overexpression. 
     
     
         2 . The method of  claim 1 , the immune-related diseases are one selected from the group consisting of autoimmune diseases, graft versus host diseases, organ transplant rejection, asthma, atopic dermatitis, acute and chronic inflammatory diseases, cardiovascular diseases and cognitive disorders. 
     
     
         3 . The method of  claim 1 , the proliferation of activated T cells is inhibited by the Treg cells overexpressing Lrig-1 protein.

Join the waitlist — get patent alerts

Track US2022135662A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.